• Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of , implying an upside potential of more than 150%.

• The company and its partner Novartis AG (NYSE: NVS) recently shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.

• It outlined progress on its global Phase 2/3 study in ambulatory COVID-19 patients.

• Interim data from EMPATHY Phase 2/3 trial is expected in H2 2021, and complete topline data expected in early 2022.

• The company started trading in the U.S market just a month back, wherein it sold 3 million shares at $21.25 each.

• The stock is already trading on the Swiss exchange since 2014.

• Price Action: MOLN shares are up 3.3% at $19.88 during the premarket session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159

• Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.